We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Boston Pharma gets $600mm Series A commitment from Gurnet Point Capital
19 Sep 2017
Executive Summary
Gurnet Point Capital committed $600mm in Series A financing to Boston Pharmaceuticals Inc., a company founded in June 2015 by Gurnet that plans to acquire drug candidates and de-risk them via a new development model.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?